Silence Therapeutics (SLN) AI Stock Analysis

• Market Cap: $203.11M
• Dividend Yield: N/A
• Average Volume (3M): 101.05K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.04
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 116
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.15
• Shares Outstanding: 47,233,948
• 10 Day Avg. Volume: 169,902
• 30 Day Avg. Volume: 101,050
• PEG Ratio: 0.07
• Price to Book (P/B): 0.79
• Price to Sales (P/S): 2.45
• P/FCF Ratio: -1.56
• Enterprise Value/Market Cap: 0.65
• Enterprise Value/Revenue: 5.30
• Enterprise Value/Gross Profit: 5.71
• Enterprise Value/Ebitda: -2.05
• 1Y Price Target: $75.00
• Price Target Upside: 1644.19% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: $5.00 ▲(16.28% Upside)

The score is primarily held back by weak financial performance (large losses and worsening cash burn), with technicals also leaning soft (below key moving averages and negative MACD). Pipeline progress from the Phase 2 enrollment completion provides a modest offset, while valuation is difficult to support due to negative earnings and no dividend data.

Positive Factors

Balance Sheet Strength

Very low leverage and a negligible debt-to-equity profile materially reduce refinancing and interest-rate exposure for a cash-burning biotech. This structural flexibility supports continued R&D and partnership deals, giving management time to progress trials without urgent debt pressures.

Revenue Quality & Gross Margins

Multi-year revenue growth and high gross margins imply attractive underlying product/partner economics when milestones convert. Durable gross economics increase potential operating leverage as revenue stabilizes, making future profitability more achievable if expense growth is controlled.

Pipeline De-risking (Phase 2)

Completing Phase 2 enrollment is a structural milestone that reduces clinical development risk and sets a clear medium-term catalyst (trial readout). Successful results would materially change commercialization prospects and partnership leverage; the milestone itself improves program credibility.

Negative Factors

Worsening Cash Burn

Consistent negative operating and free cash flow that worsened year-over-year signals growing cash burn and dependence on external funding or partnership receipts. Over a 2–6 month horizon this elevates funding risk and could force dilutive financings or reduced program spend if inflows don't arrive.

Deepening Losses

Widening operating and net losses reflect that development and SG&A expense intensity still overwhelm revenue. Persistently negative profitability erodes equity cushions and reduces optionality for strategic investments, making sustainable long-term progress contingent on funding or dramatic revenue inflection.

Leadership Transition Risk

An unexpected CEO departure and interim leadership create governance and execution uncertainty during a critical clinical window. Short-term disruptions can slow fundraising, partner negotiations, and trial execution, raising operational risk over the next several months until permanent leadership is in place.

Silence Therapeutics Business Overview & Revenue Model

Company Description

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.

How the Company Makes Money

Silence Therapeutics generates revenue through multiple streams, including collaborations and partnerships with pharmaceutical companies for the development of RNA-based therapies. The company often engages in licensing agreements that provide upfront payments, milestone payments based on the progress of drug candidates, and royalties from any resulting sales of products developed through these collaborations. Additionally, Silence Therapeutics may receive funding through grants or government programs aimed at supporting innovative healthcare solutions. Their strategic partnerships with larger pharmaceutical entities enhance their financial stability and expand their research capabilities, contributing significantly to their earnings.

Silence Therapeutics Financial Statement Overview

Summary

Overall financials are pressured by deep operating/net losses and worsening negative operating/free cash flow in TTM, despite strong multi-year revenue growth and very low leverage. The balance sheet is a relative strength, but declining TTM revenue and accelerating cash burn raise funding risk.

Income Statement

Revenue has grown strongly over the multi-year period (2020–2024), but TTM (Trailing-Twelve-Months) revenue declined sharply versus the prior year, signaling volatility typical of milestone/partner-driven biotech revenue. Profitability remains weak: despite a very high TTM (Trailing-Twelve-Months) gross margin, operating and net results are deeply negative, with losses widening again in TTM (Trailing-Twelve-Months) versus 2024. Overall, the business shows improving gross economics, but operating expense intensity is still overwhelming the revenue base.

Balance Sheet

The balance sheet is a relative strength: debt is extremely low across periods, with a negligible debt-to-equity profile, limiting refinancing and interest-rate risk. Assets remain sizable, and equity is still positive, though equity has declined materially from 2024 to TTM (Trailing-Twelve-Months), consistent with ongoing losses and cash burn. Bottom line: low leverage provides flexibility, but continued losses are eroding the equity cushion over time.

Cash Flow

Cash generation is the key weakness. Operating cash flow and free cash flow are solidly negative in 2022–TTM (Trailing-Twelve-Months), and TTM (Trailing-Twelve-Months) free cash flow deteriorated further versus 2024, indicating an increasing cash burn rate. While free cash flow broadly tracks reported losses (suggesting losses are not purely accounting-driven), the company remains dependent on external funding or partnership inflows to sustain operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	24.85M	43.26M	25.38M	21.66M	12.41M	5.48M
Gross Profit	23.04M	31.45M	15.06M	8.19M	4.96M	1.72M
EBITDA	-64.37M	-48.99M	-49.78M	-60.44M	-45.42M	-35.53M
Net Income	-62.67M	-45.31M	-43.27M	-50.33M	-39.41M	-32.55M
Balance Sheet
Total Assets	146.79M	202.63M	119.45M	107.50M	96.19M	85.97M
Cash, Cash Equivalents and Short-Term Investments	102.19M	147.33M	68.79M	71.14M	73.54M	37.45M
Total Debt	182.00K	117.00K	346.00K	446.00K	137.00K	341.00K
Total Liabilities	72.73M	68.61M	97.45M	85.43M	87.67M	76.91M
Stockholders Equity	74.06M	134.02M	21.99M	22.07M	8.53M	9.06M
Cash Flow
Free Cash Flow	-69.96M	-67.85M	-39.40M	-57.59M	7.39M	-11.29M
Operating Cash Flow	-69.85M	-67.64M	-39.35M	-57.04M	9.19M	-10.78M
Investing Cash Flow	73.47M	-21.97M	16.43M	-20.50M	11.71M	9.62M
Financing Cash Flow	19.89M	142.09M	25.16M	52.58M	41.45M	15.43M

Silence Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.30
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SLN, the sentiment is Negative. The current price of 4.3 is below the 20-day moving average (MA) of 5.36, below the 50-day MA of 5.96, and below the 200-day MA of 5.61, indicating a bearish trend. The MACD of -0.37 indicates Positive momentum. The RSI at 27.80 is Positive, neither overbought nor oversold. The STOCH value of 9.93 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SLN.

Silence Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ABEO	60 Neutral	$275.29M	4.36	75.90%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VOR	50 Neutral	$271.69M	-0.03	―	―	―	-1072.48%
SLN	47 Neutral	$203.11M	-2.57	―	―	―	―
GALT	46 Neutral	$190.86M	-5.01	―	―	―	18.82%
HUMA	45 Neutral	$184.93M	-4.01	―	―	―	82.23%

Silence Therapeutics Corporate Events

Silence Therapeutics Appoints CFO Rhonda Hellums to Board

On December 18, 2025, Silence Therapeutics plc appointed its Executive Vice President and Chief Financial Officer, Rhonda Hellums, to the company’s Board of Directors as an executive director, with her initial term running until the end of the 2026 Annual General Meeting of Shareholders. Hellums will serve on the board without additional compensation and will not sit on any board committees, and the company emphasized that her appointment did not arise from any special arrangements, family relationships, or related-party transactions, underlining standard governance practices for stakeholders monitoring board independence and oversight.

The most recent analyst rating on (SLN) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Silence Therapeutics stock, see the SLN Stock Forecast page.

Silence Therapeutics Announces CEO Departure and Leadership Changes

On December 15, 2025, Silence Therapeutics announced the departure of Craig Tooman as CEO and Board member, effective December 14, 2025. Iain Ross, Chairman of the Board, has been appointed as interim principal executive officer, while James Ede-Golightly has rejoined the Board as a director. These leadership changes reflect the company’s ongoing commitment to advancing its commercial and scientific pipeline, with the company in strong financial and operational health.

The most recent analyst rating on (SLN) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Silence Therapeutics stock, see the SLN Stock Forecast page.